Ruplizumab Explained

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]

Notes and References

  1. Liossis SN, Sfikakis PP . Costimulation blockade in the treatment of rheumatic diseases . BioDrugs . 18 . 2 . 95–102 . 2004 . 15046525 . 10.2165/00063030-200418020-00003 . 24762590 .
  2. Nakamura M, Tanaka Y, Satoh T, Kawai M, Hirakata M, Kaburaki J, Kawakami Y, Ikeda Y, Kuwana M . 6 . Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism . Rheumatology . 45 . 2 . 150–6 . February 2006 . 16188945 . 10.1093/rheumatology/kei118 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ruplizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.